Product Liability Lawyer Blog
Depo-Provera (depot medroxyprogesterone acetate, often shortened to DMPA) has been used for decades as an injectable form of birth control. For many patients, it’s been prescribed for convenience and reliability. In 2026, however, Depo-Provera is also at the center of rapidly evolving product-liability litigation focused on allegations that repeated/long-term use may be associated with an increased risk of meningioma, a typically noncancerous intracranial tumor that can still cause serious neurological harm.
Our Depo-Provera lawsuit claims attorneys explain what has changed recently, what plaintiffs are alleging, how these cases are evaluated, and what documentation tends to matter most when investigating a potential claim. This article is written for patients and families, not for other lawyers, so it focuses on practical realities rather than legal jargon.